Impact of pre-enrolment medication use on clinical outcomes in SUMMIT Source: ERJ Open Res, 5 (1) 00203-2018; 10.1183/23120541.00203-2018 Year: 2019
Clinical and economic outcomes following 52-week add-on omalizumab Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013
Is there a place for anti-remodelling drugs in asthma which may not display immediate clinical efficacy? Source: Eur Respir J 2004; 24: 1-2 Year: 2004
Clinical observations on inhaled drug adherence Source: Eur Respir J 2005; 26: Suppl. 49, 127s Year: 2005
Clinical and economic impact of inhaled corticosteroid withdrawal in Spanish COPD patients treated with triple therapy Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies Year: 2021
SABINA: global programme to evaluate prescriptions and clinical outcomes related to short-acting ß2 -agonist use in asthma Source: Eur Respir J, 55 (2) 1901858; 10.1183/13993003.01858-2019 Year: 2020
Self-care behavior for medications use and treatment outcome in elderly with asthma Source: Annual Congress 2010 - Dysfunctional breathing, asthma and respiratory physiotherapy problems Year: 2010
Impact of add-on medications on patient‘s satisfaction in patients with asthma Source: Eur Respir J 2005; 26: Suppl. 49, 273s Year: 2005
Safety profile of tiotropium add-on therapy in paediatric patients by gender Source: International Congress 2018 – Innovative therapies in asthma and COPD Year: 2018
Changes in the use of anti-asthmatic medication in an international cohort Source: Eur Respir J 2005; 26: 1047-1055 Year: 2005
Study of the adherence to treatment in asthma according to clinical, psychological and educational parameters Source: Eur Respir J 2001; 18: Suppl. 33, 44s Year: 2001
Time to ban short-acting ß-agonists and use anti-inflammatory treatment as required to improve outcomes Source: Virtual Congress 2021 – Wheezing illnesses along the life span Year: 2021
Effects of pharmacist interventions to inhalation medication adherence and lung functions in COPD patients at one stop service clinic Source: International Congress 2014 – COPD exacerbations Year: 2014
Clinical and economic impact of an improvement in adherence based on specific attributes of single-inhaler triple therapies in COPD patients Source: International Congress 2019 – Inhalers: adherence and preference Year: 2019
Neuropsychiatric adverse drug reactions in children initiated on montelukast in real-life practice Source: Eur Respir J, 50 (2) 1700148; 10.1183/13993003.00148-2017 Year: 2017
Neuropsychiatric adverse drug reactions in children initiated on montelukast in real-life practice Source: Eur Respir J, 50 (5) 1701984; 10.1183/13993003.01984-2017 Year: 2017
Neuropsychiatric adverse drug reactions in children initiated on montelukast in real-life practice Source: Eur Respir J, 50 (5) 1702135; 10.1183/13993003.02135-2017 Year: 2017
Clinical benefits and safety of long term treatment with Montelukast in children with asthma Source: Eur Respir J 2002; 20: Suppl. 38, 525s Year: 2002
Predictors of effectiveness of omalizumab treatment in patients with severe asthma recruited in a real-life setting Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015